Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497404 · ClinicalTrials.gov registry record · Phase 2
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02497404 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 40 participants.
The verdict
NCT02497404, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in complete remission (CR).
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Alemtuzumab
- RADIATION Total Body Irradiation
- DRUG 5-Azacytidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-02-13 |
| Est. Completion | 2021-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497404
The ClinicalTrials.gov registry entry for NCT02497404 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT02497404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497404 about?
NCT02497404 is a clinical study titled "Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR". The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in complete remission (CR).
What is the current status of trial NCT02497404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-02-13. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT02497404?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Alemtuzumab (DRUG), Total Body Irradiation (RADIATION), 5-Azacytidine (DRUG).
Who is sponsoring clinical trial NCT02497404?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.